Journal article
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study
R Dienstmann, MJ Mason, FA Sinicrope, AI Phipps, S Tejpar, A Nesbakken, SA Danielsen, A Sveen, DD Buchanan, M Clendenning, C Rosty, B Bot, SR Alberts, J Milburn Jessup, RA Lothe, M Delorenzi, PA Newcomb, D Sargent, J Guinney
ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2017
Abstract
Background: TNM staging alone does not accurately predict outcome in colon cancer (CC) patients who may be eligible for adjuvant chemotherapy. It is unknown to what extent the molecular markers microsatellite instability (MSI) and mutations in BRAF or KRAS improve prognostic estimation in multivariable models that include detailed clinicopathological annotation. Patients and methods: After imputation of missing at random data, a subset of patients accrued in phase 3 trials with adjuvant chemotherapy (n = 3016)-N0147 (NCT00079274) and PETACC3 (NCT00026273)-was aggregated to construct multivariable Cox models for 5-year overall survival that were subsequently validated internally in the remain..
View full abstractGrants
Awarded by National Cancer Institute (NCI), National Institutes of Health (NIH)
Awarded by NCI/NIH
Awarded by NATIONAL CANCER INSTITUTE
Funding Acknowledgements
This work was partially supported by grant UM1 CA167551 from the National Cancer Institute (NCI), National Institutes of Health (NIH), and through cooperative agreements with members of the Colon Cancer Family Registry (CCFR) and Principal Investigators. Centers contributing to this analysis include the Seattle Colorectal Cancer Family Registry (U01/U24CA074794), Australasian Colorectal Cancer Family Registry (U01 CA074778 and U01/U24 CA097735), Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (U01/U24 CA074800), and Ontario Familial Colorectal Cancer Registry (U01/U24 CA074783). This work was also supported by NCI/NIH grant K07CA172298 and K05CA152715 (to AIP). The content of this article does not necessarily reflect the views or policies of the NIH or any of the collaborating centers in the CCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This study was partly supported by the "Norwegian Cancer Society" and the "Research Council of Norway" (no grants apply).